Literature DB >> 10946066

Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion.

J M Budde1, D A Velez, Z Zhao, K L Clark, C D Morris, S Muraki, R A Guyton, J Vinten-Johansen.   

Abstract

OBJECTIVE: The purpose of this study was to compare protective effects of AMP579 and adenosine (Ado) at reperfusion (R) on inhibition of polymorphonuclear neutrophil (PMN) activation, PMN-mediated injury to coronary artery endothelium, and final infarct size.
METHODS: In anesthetized dogs, 1 h of left anterior descending coronary artery occlusion was followed by 24 h R and drugs were administered at R. Control (n=8, saline control), AMPI (n=7, AMP579, 50 microg/kg i.v. bolus followed by 3 microg/kg/min for 2 h), AMPII (n=7, AMP579, 50 microg/kg i.v. bolus), AMPIII (n=7, AMP579, 3 microg/kg/min i.v. for 2 h), and Ado (n=7, adenosine, 140 microg/kg/min i.v. for 2 h).
RESULTS: AMP579 in vitro directly inhibited superoxide radical (O(-)(2)) generation (nM/5x10(6) PMNs) from PMNs dose-dependently (from 17+/-1* at 10 nM to 2+/-0.2* at 10 microM vs. activated 30+/-2). However, inhibition of O(-)(2) generation by Ado at each concentration was significantly less than for AMP579. The IC(50) value for AMP579 (0.09+/-0.02 microM) on O(-)(2) generation was significantly less than that of Ado (3.9+/-1. 1 microM). Adherence of unstimulated PMN to postischemic coronary artery endothelium (PMNs/mm(2)) was attenuated in AMPI and AMPIII vs. Control (60+/-3* and 58+/-3* vs. Control 110+/-4), while Ado partially attenuated PMN adherence (98+/-3*). Accordingly, endothelial-dependent vascular relaxation was significantly greater in AMPI and AMPIII vs. Ado. At 24 h R, myocardial blood flow (MBF, ml/min/g) in the area at risk (AAR), confirmed by colored microspheres, in AMPI and AMPIII was significantly improved (0.8+/-0. 1* and 0.7+/-0.1* vs. Control 0.3+/-0.04). Infarct size (IS, TTC staining) in AMPI and AMPIII was significantly reduced from 38+/-3% in Control to 21+/-4%* and 22+/-3%*, respectively, confirmed by lower plasma creatine kinase activity (I.U./g protein) in these two groups (27+/-6* and 32+/-2* vs. 49+/-3). Cardiac myeloperoxidase activity (MPO, Abs/min) in the AAR was significantly reduced in AMPI and AMPIII vs. Control (36+/-11* and 35+/-10* vs. 89+/-10). However, changes in MBF, IS and MPO were not significantly altered by Ado.
CONCLUSIONS: These data suggest that continuous infusion of AMP579 at R is more potent than adenosine in attenuating R injury, and AMP579-induced cardioprotection involves inhibition of PMN-induced vascular and myocardial tissue injury. *P<0.05 vs. Control.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946066     DOI: 10.1016/s0008-6363(00)00115-2

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

1.  Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury.

Authors:  Michael Koeppen; Patrick N Harter; Stephanie Bonney; Megan Bonney; Susan Reithel; Cornelia Zachskorn; Michel Mittelbronn; Tobias Eckle
Journal:  Anesthesiology       Date:  2012-06       Impact factor: 7.892

Review 2.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

3.  A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.

Authors:  John A Auchampach; Zhe-Dong Ge; Tina C Wan; Jeannine Moore; Garrett J Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-04-10       Impact factor: 4.733

Review 4.  Hydrogen sulfide-mediated myocardial pre- and post-conditioning.

Authors:  Benjamin L Predmore; David J Lefer
Journal:  Expert Rev Clin Pharmacol       Date:  2011-01       Impact factor: 5.045

Review 5.  Protective ischaemia in patients: preconditioning and postconditioning.

Authors:  Asger Granfeldt; David J Lefer; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2009-04-27       Impact factor: 10.787

6.  AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts.

Authors:  Yanping Liu; Xiulan Yang; Xi-Ming Yang; Sheree Walker; Karina Förster; Michael V Cohen; Thomas Krieg; James M Downey
Journal:  Basic Res Cardiol       Date:  2010-01       Impact factor: 17.165

Review 7.  Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.

Authors:  Michael V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

8.  Ischaemic preconditioning and postconditioning do not affect adenosine A(1) and A (2A) receptor sensitivity.

Authors:  Niels P Riksen; Abigail Wynne; Derek M Yellon; Derek J Hausenloy
Journal:  Cardiovasc Drugs Ther       Date:  2009-10       Impact factor: 3.727

Review 9.  Transplantation of Hearts Donated after Circulatory Death.

Authors:  Christopher W White; Simon J Messer; Stephen R Large; Jennifer Conway; Daniel H Kim; Demetrios J Kutsogiannis; Jayan Nagendran; Darren H Freed
Journal:  Front Cardiovasc Med       Date:  2018-02-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.